INIFY LABORATORIES AB
INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.
Market Cap & Net Worth: INIFY LABORATORIES AB (WY60)
INIFY LABORATORIES AB (F:WY60) has a market capitalization of $24.30 Million (€23.67 Million) as of March 18, 2026. Listed on the F stock exchange, this Germany-based company holds position #46751 globally and #7789 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying INIFY LABORATORIES AB's stock price €0.30 by its total outstanding shares 78903416 (78.90 Million).
INIFY LABORATORIES AB Market Cap History: 2022 to 2026
INIFY LABORATORIES AB's market capitalization history from 2022 to 2026. Data shows change from $62.04 Million to $24.30 Million (-19.93% CAGR).
INIFY LABORATORIES AB Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how INIFY LABORATORIES AB's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of WY60 by Market Capitalization
Companies near INIFY LABORATORIES AB in the global market cap rankings as of March 18, 2026.
Key companies related to INIFY LABORATORIES AB by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #91 globally with a market cap of $176.18 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #154 globally with a market cap of $120.38 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.34 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #512 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #91 | Thermo Fisher Scientific Inc | NYSE:TMO | $176.18 Billion | $470.00 |
| #154 | Danaher Corporation | NYSE:DHR | $120.38 Billion | $191.39 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.34 Billion | $586.37 |
| #512 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
INIFY LABORATORIES AB Historical Marketcap From 2022 to 2026
Between 2022 and today, INIFY LABORATORIES AB's market cap moved from $62.04 Million to $ 24.30 Million, with a yearly change of -19.93%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €24.30 Million | +32.74% |
| 2025 | €18.30 Million | -34.30% |
| 2024 | €27.86 Million | -64.68% |
| 2023 | €78.89 Million | +27.15% |
| 2022 | €62.04 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of INIFY LABORATORIES AB was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $24.30 Million USD |
| MoneyControl | $24.30 Million USD |
| MarketWatch | $24.30 Million USD |
| marketcap.company | $24.30 Million USD |
| Reuters | $24.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.